Clinical Trials
82 trialsPIKHER2
Institut Paoli-Calmettes
BURAN
Adlai Nortye Biopharma Co., Ltd.
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
LOGIC-2
Pfizer
ENDOPIK
ARCAGY/ GINECO GROUP
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
Canadian Cancer Trials Group
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
BKM120
National Cancer Centre, Singapore
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Memorial Sloan Kettering Cancer Center
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Rutgers, The State University of New Jersey
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
Roswell Park Cancer Institute
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Indiana University
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
Prince of Songkla University
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
University of Chicago
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Neoadjuvant BKM120 in High-risk Prostate Cancer
University of California, San Francisco
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
Novartis
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis
LeeBLet
Novartis
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Novartis
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
Novartis
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Novartis
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
Novartis
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Novartis
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Novartis
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis
A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
Novartis
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
SOLTI Breast Cancer Research Group
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array BioPharma
BELLE-2
Novartis
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
SCRI Development Innovations, LLC
B-YOND
Novartis
NeoPHOEBE
Novartis
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Emory University
BKM120
University of Oxford
PIK-ORL
Centre Leon Berard
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
Novartis
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Dana-Farber Cancer Institute
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
SCRI Development Innovations, LLC
BKM120+Abiraterone Acetate for Metastatic CRPC
Dana-Farber Cancer Institute
BELLE-3
Novartis
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Stanford University
BKM120 For Triple Negative Breast Cancer
Dana-Farber Cancer Institute
SIGNATURE
Novartis
BASALT-2
Novartis